Furthermore, physiologic hypoxia promotes maintenance of CML-LSCs independently of BCR-ABL activity [167], suggesting that targeting HIF1α in combination with a TKI could lead to complete eradication of LSCs. The gene discussed is HIF1A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.